Home › Stat-Dx POC Syndromic Testing Platform, Respiratory MDx Receive CE-IVD Mark

Stat-Dx POC Syndromic Testing Platform, Respiratory MDx Receive CE-IVD Mark

Jan 08, 2018

NEW YORK (GenomeWeb) – Molecular diagnostics developer Stat-Dx has received CE-IVD marking on a syndromic testing platform and a respiratory panel, the firm announced today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
15
Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

  2. Roche Diagnostics' Revenues Grow 6 Percent in First Nine Months of 2018

  3. Roche Patent Invalidation Affirmed in TB Testing Lawsuit Against Cepheid

  4. FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug

  5. Abbott Q3 Dx Business Grows 43 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.